A Phase 2 interventional study of AX200 (G-CSF) in Cerebral Stroke, sponsored by Axaron Bioscience AG. Completed at 2 sites in Germany. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2007-07-25.
Sponsored by Axaron Bioscience AG · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 356 studies in Stroke with a site in Germany — 51 open to participants now, 66 under way, 8 of them phase 3. Stroke · Germany.
Among the 356 studies in Stroke with a site in Germany, this one is the 168th largest by enrollment of the 222 interventional ones that give a count, is one of 5 that started in 2004, is one of 31 in phase 2, and was the 14th registered.
8,269 studies on the registry are indexed under Stroke; 2,062 are open to participants now.
Browse Stroke studies →51 of the 356 studies in Stroke with a site in Germany are open now. Recruiting first, the newest first:
Hospital Universitari Vall d'Hebron Research Institute · Sites in Germany, Belgium, Italy and 3 more countries
Ages 18+
Giuseppe Tarantini · Sites in Germany
Ages 18–65
Dr. Yaroslav Winter · Sites in Germany, Czechia, Italy and 1 more country
Johannes Dorst · Sites in Germany
Ages 18+
Sigmund Freud PrivatUniversitat · Sites in Germany, Austria, Switzerland
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 1,419 Stroke studies recruiting now, 695 (49%) set no upper age limit and 283 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
356 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 43 · Phase 3 62 · Phase 4 17
First in 1994; this study’s year is marked. 5 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 42 is below the median of 48 across 6,037 interventional studies indexed under Stroke.
Median enrollment 200 across the 222 interventional studies, 368 across the 133 observational. Of the 242 that completed or were terminated, 52 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
125 of 356 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Axaron Bioscience AG as lead sponsor.
Axaron Bioscience AG has 1 study filed under Stroke — fewer than ten, so there is no comparison to draw.
17 of the studies in Stroke with a site in Germany that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05691244Phase 3Pharmazz, Inc.Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke | 2027-09 |
| NCT07357285iVascular S.L.U.Safety and Efficacy Evaluation of the iNstroke 4F Thromboaspiration Catheter in Patients With Acute Ischaemic Stroke Due to Primary Distal Medium Vessel Occlusions (DMVO) | 2026-11 |
| NCT07885189University Hospital TuebingenLong-Term Cognitive Recovery After Arteria Cerebri Media Ischemia: A Digital Assessment Using the TuCAN-App | 2026-11 |
| NCT06121336Ludwig-Maximilians - University of MunichPRecisiOn Medicine In StrokE: Evolution of Plasma Brain-Derived Tau in Acute Stroke | 2026-12-31 |
| NCT07299994Sigmund Freud PrivatUniversitatEfficacy and Safety of Intravenous Thrombolysis in Branch Atheromatous Disease | 2026-12-31 |
Add all 17 to your calendar (.ics) → With an account.
Among the 356 studies in Stroke with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The AXIS study is a randomized, double-blind, placebo-controlled, dose-escalating phase IIa trial to investigate treatment with AX200 (granulocyte-colony stimulating factor; G-CSF) for acute ischemic stroke. The primary objective of the present phase IIa study is to assess the safety and tolerability of AX200 compared to placebo in subjects suffering from acute stroke. The secondary objective is to assess the effect of AX200 on subject outcome in comparison to placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug pages: Granulocyte Colony-Stimulating Factor · Filgrastim
Safety
Neurological outcome
ischemic lesion growth
The record gives a start of Dec 2004 and a completion of Mar 2007. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2007. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Granulocyte Colony-Stimulating Factor · Filgrastim